<DOC>
	<DOC>NCT00912002</DOC>
	<brief_summary>A single dose, open label study to characterize the routes of elimination and determine the mass balance of MK-0941. A single 40 mg dose of MK-0941 will be given orally to male participants with type 2 diabetes. After drug administration, blood, urine, and fecal samples will be collected to determine relative quantities of 14C-labeled MK-0941.</brief_summary>
	<brief_title>A Study of Absorption, Metabolism, Excretion and Mass Balance After a Single Dose Administration of MK-0941 (MK-0941-016)(COMPLETED)</brief_title>
	<detailed_description />
	<criteria>Subject has been diagnosed with type 2 diabetes, and is being treated with diet and exercise or with an oral antihyperglycemic agent Subject is willing to follow the American Heart Association diet and exercise program throughout the study Subject is a nonsmoker and/or has not used nicotine products for at least 6 months Subject has a history of stroke, seizures, or major neurological disorder Subject has a history of neoplastic disease Subject has recently had abnormal bowel habits, such as diarrhea, loose stools or constipation Subject has a history of type 1 diabetes mellitus Subject has received insulin within the past 12 weeks Subject has a recent history of eye infection Subject has been diagnosed with glaucoma or is blind Subject consumes more than 3 alcoholic beverages per day Subject consumes more than 6 servings of coffee, tea, cola per day Subject has had major surgery, donated or lost blood in the past 4 weeks Subject has multiple or severe allergies to any food or drugs</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>